Imidazoline receptor type 2 (I2 receptor)

Imidazoline receptor type 2 is a putative receptor site primarily characterized by high-affinity binding of imidazoline compounds such as idazoxan and 2-BFI, and is currently believed to correspond to several proteins, notably including a site on the outer mitochondrial membrane (likely an allosteric site on monoamine oxidase) and brain creatine kinase[7][1]. Unlike classical GPCRs, its molecular identity remains incompletely defined. The I2 receptor modulates chronic and tonic pain (but not acute pain), and ligands acting on this receptor have demonstrated analgesic properties in preclinical and early clinical studies, with potential as novel non-opioid treatments for chronic pain syndromes[7][3][5]. I2 receptor agonists also exhibit neuroprotective effects, modulate body temperature, and may reduce opioid tolerance and withdrawal, making them promising therapeutic coadjuvants[3][7]. While considered an emerging drug target, selective pharmacology and precise molecular targets are still being clarified. Key points: - I2 receptor ligands are being developed for pain management, particularly for chronic and neuropathic pain (e.g., CR4056 is in phase II clinical trials)[7][3]. - Agmatine and harmane are proposed endogenous ligands[5]. - Safety profile is still being established; central effects and off-target interactions (especially with alpha-2 adrenergic receptors) require careful evaluation[4][5][7].

Other names

Imidazoline I2 receptorI2 binding siteI2-imidazoline receptor

Allosteric modulation of monoamine oxidase, Analgesic effect via chronic pain pathways, Potentiation of opioid antinociception, Decrease of opioid tolerance and withdrawal symptoms, Modulation of body temperature, Neuroprotection